Sign in
Not yet recruitingPhase 1/2

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy

Key facts

Who runs it
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Where
China8 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
55 people, planned
Started
Aug 2026
Expected to end
Mar 2030
Type of study
Interventional
Treatments tested
  • FKC289 injection
Record updated
14 August 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Voluntarily signed the informed consent form (ICF)
  • Aged between 18-70 years old (inclusive)
  • Histologically confirmed diagnosis of primary membranous nephropathy by renal biopsy obtained within the past 2 years
  • Relapsed or refractory disease
  • Anti-PLA2R antibody > 50 RU/mL
  • 24-hour urine protein > 3.5 g at screening
  • No active systemic infection (e.g., infectious pneumonia, pulmonary tuberculosis) within 2 weeks prior to leukapheresis
  • Adequate bone marrow and major organ function (including hepatic, renal, cardiac, and pulmonary)

Who cannot take part

  • Secondary membranous nephropathy or patients with a prior diagnosis of other renal diseases
  • Presence of any clinically significant cardiovascular disease within 6 months prior to screening
  • Clinically significant central nervous system (CNS) disease or pathological abnormality
  • History of solid organ transplantation (e.g., heart, lung, kidney, liver)
  • Presence of complete intestinal obstruction
  • Moderate to severe pleural effusion or ascites that is difficult to control with conventional treatment and requires continuous catheter drainage

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory Primary Membranous Nephropathy.The primary objectives are to assess the safety of FKC289 and to establish the recommended Phase II dose (RP2D).And this Phase II study is designed to evaluate the efficacy of FKC289.The primary objectives are to assess proportion of subjects achieving clinical response (including complete or partial response) at 6 months.

The group in the trial

  • FKC289 injectionTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07765537, who can take part
Record updated
14 August 2026